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Abstract
Molecular docking has been developed and improving for many years, but its ability to
bring a medicine to the drug market effectively is still generally questioned. In this
chapter, we introduce several successful cases including drugs for treatment of HIV,
cancers, and other prevalent diseases. The technical details such as docking software,
protein data bank (PDB) structures, and other computational methods employed are also
collected and displayed. In most of the cases, the structures of drugs or drug candidates
and the interacting residues on the target proteins are also presented. In addition, a few
successful examples of drug repurposing using molecular docking are mentioned in this
chapter. It should provide us with confidence that the docking will be extensively
employed in the industry and basic research. Moreover, we should actively apply molec-
ular docking and related technology to create new therapies for diseases.
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1. Introduction
Molecular docking is one of many computational tools that can be used in drug discovery [1–4].
It is a form of structure-based drug discovery that quantifies the binding affinities between
small molecules and macromolecular targets (proteins). The first step in molecular docking is
choosing a drug target. Any macromolecule can be used as a target; some very common
targets include enzymes and regulatory elements. Next, the three-dimensional structure must
be determined or predicted; high resolution structures can be determined using X-rays, NMR,
or electron microscopy (EM). Thousands of popular targets have solved structures available on
the protein data bank (PDB) [5]. Many drug targets have known binding sites; if not, software
that can predict potential binding sites for different ligands have been developed. Docking
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studies can be performed using known ligands (naturally occurring molecules or known
drugs) or novel ligands. Virtual screening (i.e. identifying novel ligands with molecular
docking) provides an extremely useful (but time consuming) method of drug discovery
because molecules can be designed to have high binding affinity to a very specific site.
Docking studies are often validated using further computational methods, such as molecular
dynamic simulation. The most successful candidates from computational trials can be tested
in vitro or in vivo, and eventually progress to clinical trials (Figure 1).
Figure 1. A brief flowchart of novel drug discovery procedure.
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It is believed that a searching algorithm, which assists in thoroughly and efficiently exploring
possible positions, orientations and conformations of potential drugs and the target proteins,
and a scoring function, which assists in precisely and correctly identifying the most energetically
favorable binding poses, are two most important components of a molecular docking programs.
However, some other factors will affect the effectiveness and accuracy of molecular docking,
such as the availability and quality of a determined or predicted structure of the target protein,
the conformational changes of the target proteins after the drug binding, and the identification
of potential binding sites. As those mentioned in previous chapters, many commercial and
academic docking search algorithms, scoring functions, and software packages have been
developed and improved in the past decades. However, it is still questioned if there are any
successful stories in which molecular docking have helped to bring a drug to the market.
Although many molecular docking algorithms have been developed and improved for many
decades, biomedical laboratories or pharmaceutical companies used to be hesitant to apply
this technology to drug screening. Here are some possible reasons:
1. The “force fields” which describe the intra- and inter-molecular interaction energies were
not accurate and precise enough to estimate or calculate the binding affinities between
proteins and potential binding drugs.
2. The computer was not “fast” enough to calculate the interacting energy of many possible
binding “conformations” of one or many possible binding compound(s) using a sophisti-
cated model taking account into all the factors, components, and conditions of molecular
interactions.
3. The number of binding complex structures was not large enough and the resolution of
available structures was not good.
4. The searching/sampling algorithms to explore the possible binding orientations and con-
formations were not efficient to identify possible binding poses with reasonable time.
These reasons and concerns are all tightly cross-linked together, and, fortunately, have been
dramatically improved in the past years. For example, the number of structures on PDB has
increased from 47,605 to 133,759 since 2007 [6]. The resolution of determined structures has
significantly improved. Therefore, the accuracy of both physics-based and knowledge-based
scoring functions which assist researchers in identifying the most energy favorable binding
poses and estimating binding affinities have been improved. The substantial improvement in
both computer hardware and software also make it possible to screen a large number of
natural and artificial compounds and search the best binding poses efficiently.
When we attempt to dock a compound to a target protein, often we need to use other
computational methods before docking or in parallel. For instance, we may need to do
structure prediction if the structure of the target protein has not yet been determined. The
accumulated PDB structures with good resolution and the accurate structure prediction
algorithms make it possible for researchers to obtain reliable structural models to perform
molecular docking experiments. The enhanced quantity, quality, and diversity of protein-
compound complex structures provide solid basis for creation of accurate binding site
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prediction methods, and they help reduce the searching surface area on the target proteins
for docking algorithms [7–9]. Other computational methods such as pharmacophore and
quantitative structure-activity relationship (QSAR) models can be used prior to the molecu-
lar docking to reduce computational load and time [10–12]. In summary, the technology of
molecular docking has matured and been applied in different stages of the drug discovery
process. The successful stories have not been mentioned often and are not widely known.
They will be introduced in this chapter.
2. Identification of medicine for HIV
The human immunodeficiency virus (HIV) epidemic around the world has pushed massive
amounts of money into research that looks for ways to help treat and prevent this virus.
Because bringing a drug into the market can take many years and cost astronomical amounts
of money, it is of the utmost importance of researchers to use a cost effective ways to find these
new therapeutics. Computational methods have been gradually becoming commonplace in
drug design research. These methods have been either confirming established research, dis-
covering new compounds, binding sites or conformations, and even allowing for the
repurposing of the drug to treat other illnesses. HIV research has seen an influx of multiple
computational methods being used to confirm discoveries of previous studies and establish
new ones. Methods such as docking and molecular dynamics are saving researchers valuable
time. These methods are also allowing research to make accurate and precise predictions of
what is going on at the molecular level. While computational drug design methods are
nowhere near replacing in vitro and in vivo testing, in silico testing is becoming increasingly
popular for researchers to validate their research or act as a starting point for in vitro testing.
This section will introduce how researchers used computational methods to help identify
drugs for HIV-1 Protease and HIV-1 Integrase. It will also discuss how these methods are being
utilized for future developments in this area of research, and how researchers were able to use
the drugs Saquinavir and Nelfinavir toward treating a disease unrelated to HIV—Chagas.
2.1. Human immunodeficiency virus
Acquired immunodeficiency syndrome (AIDS) is acquired in humans by the retrovirus HIV
[13]. HIV infects important helper T cells in the human immune system—specifically CD4+ T
cells [14]. HIV is transmitted as positive-sense, single-stranded, enveloped RNA virus. There
are currently two types of HIV that have been characterized as HIV-1 and HIV-2. HIV-1 was
the first HIV virus discovered and it is more virulent and more infective than HIV-2 [15].
After the viral capsid has entered the cell, an enzyme called reverse transcriptase liberates
the positive-sense RNA from the viral proteins and copies it into a complimentary DNA
molecule [16]. The reverse transcriptase process is very prone to errors. This characteristic
results in many mutations that make this component of HIV likely to encounter drug
resistance. For this reason, HIV reverse transcriptase is an unlikely target for HIV therapeu-
tics. The newly formed circular DNA strand and its complement form a double-stranded
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viral DNA that is transported to the nucleus. The integration of the viral DNA into the host’s
genome is carried out by the integrase enzyme [16]. The HIV virus then may remain dormant
or continue to assemble new HIV-1 virions. The plasma membrane of the host cell is the site
for the production of new HIV-1 virions. The virion buds that are produced at the plasma
membrane are cleaved by HIV-1 protease enzyme. Once the bud has been cleaved by HIV-1
protease, the internal components can assemble, and in turn create a virion capable of
infecting other cells. The two targets that computational drug researchers have focused on
significantly are HIV-1 integrase and HIV-1 protease.
2.2. HIV-1 integrase
Integrase (IN) is a retrovirus enzyme not exclusive to only HIV. This protein allows the genetic
material of the virus to be integrated into the DNA of the host cell. Integration occurs after the
double-stranded viral DNA is produced by reverse transcriptase. Once integration has com-
menced for a cell, there is no turning back. The cell is now considered a pro-virus, and it is now
a permanent carrier of the virus. In general, retroviral integrases catalyze two reactions. Both
reactions are catalyzed by the same active site on the enzyme and occur via transesterification.
2.2.1. HIV-1 integrase inhibitor—Raltegravir and its ensuing analogs
The most common inhibitors for integrase are referred to as integrase strand transfer inhibitors
(INSTIs). Mg2+ and Mn2+ are critical cofactors in the integration phase [17], and inactivating
these cofactors causes functional impairment of integrase. Most HIV-1 INSTIs contain a struc-
tural motif that coordinates the two divalent magnesium ions in the enzyme’s active site [17].
Researchers screen over 250,000 compounds to yield potent inhibitors [18]. The most active
inhibitors seemed to contain a distinct beta-diketo acid (DKA) moiety [19]. This moiety had the
ability to coordinate metal ions within the IN active site. There was similar antiviral activity
when the DKA pharmacophore was transferred to a naphthyridine carboxamide core [20]. A
class of N-alkyl hydroxypyridinone carboxylic acids was the result of the success with the
diketo acid structural analogs. These new analogs had a good pharmacokinetic profile in rats
[21]. The drug, MK-0518, also known as Raltegravir, became the most promising pyrimidinone
carboxamide derivative. Raltegravir was the first integrase inhibitor to progress to Phase III
clinical trials. While there have been multiple resistant mutations for both treatment-
experienced and treatment-naïve patients, Raltegravir still proved to be an effective IN inhib-
itor [22]. In October 2007, Raltegravir became the first FDA-approved IN inhibitor (Table 1).
To bring a single drug to the market, it can cost upwards of $2 billion [23]. Even with this, only
one in three drugs will generate enough revenue to cover the cost of the research and devel-
opment of the drug [24]. Pharmaceutical researchers and executives can see the allure of
modifying current leads on drugs, rather than trying to design a new drug. “Me-too” drugs
[18] can create an optimized drug and create vital marketplace competition, but many argue
that slight modifications are producing negligible improvements [25]. “Me-too” drug emer-
gence has seen a surge in the HIV-1 integrase inhibitor market. While Raltegravir has become
the known and widely used anti-HIV drug, amino acid mutations have already conferred
robust viral resistance of the drug [26]. This viral drug resistance normally occurs when one
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Table of various HIV-1 integrase and HIV-1 protease inhibitors
Drug Type of inhibitor Affected residues Structure
Raltegravir HIV-integrase D64
T66
E92
D116
Y143
Q148
E152
N155
S-1360 HIV-1 integrase D64
T66
D116
Y143
Q148
E152
N155
Saquinavir HIV-1 protease G84
I84
L90
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of three amino acids—Y143, Q148, or N155—mutate in conjunction with at least one other
mutation [27]. The strongest antiviral resistant mutation seems to be the Q148H integrase
mutant (IC50 > 700 nM), and G140S has been shown to restore the poor replication ability of
Q148H to wild-type levels [28]. Even though Raltegravir has seen this resistance profile,
pharmaceutical companies still spend lots of money on “me-too” research and the
Table of various HIV-1 integrase and HIV-1 protease inhibitors
Drug Type of inhibitor Affected residues Structure
Nelfinavir HIV-1 protease D30
I84
L90
Amprenavir HIV-1 protease I84
L90
I54
V82
Table 1. The various HIV-1 protease and HIV-1 integrase inhibitors and their structures. The affected residues in HIV-1
protease and HIV-1 integrase binding pocket are shown as well.
Has Molecular Docking Ever Brought us a Medicine?
http://dx.doi.org/10.5772/intechopen.72898
147
development on this drug. There should be a distinction made between me-too drugs and
second-generation drugs [18]. A second-generation inhibitor needs to exhibit a new mode of
action. Secondly, a second-generation drug needs to show significantly improved potency or
decreased toxicity. A major problem with second-generation drugs is cross resistance, so these
drugs should maintain potency, but avoid this cross-resistance.
2.2.2. Using docking studies to predict the binding mode of S-1360
It is very important to predict a bioactive conformation of a ligand, but the task becomes
difficult when the receptor site has a region with unusual conformational flexibility. With the
numerous crystal structures available for HIV-1 integrase, there are numerous differences in
the active site regions in the core domains of IN. S-1360 was one of the first beta-diketoacid IN
inhibitors to enter clinical studies. Dayam and Neamati sought to predict the bioactive (active
site bound) conformations of S-1360 [29]. To achieve this, the researchers performed extensive
docking studies with three different crystal structures. The study was extended to include
5CITEP and a bis-diketoacid (BDKA).
To predict the binding mode of S-1360, 104 unique conformations within a 20 kcal/mol energy
range were generated using catConf module of the Catalyst. All 104 conformations of S-1360
were docked into the active sites A, B, and C (PDB: 1QS4, 1BIS, and 1BL3, respectively). Based
on GOLD fitness scores, 10 conformers with highest scores were selected for further analysis.
The researchers noted that S-1360 adopted very different binding orientations inside the active
sites for A, B, and C. In the A active site, the bound conformation with the highest GOLD
fitness score was found 102 times of 200 conformations. S-1360 occupies a space near D64,
D116, N120, and Mg2+ ion. In active site B, the highly favorable conformation of S-1360 is
found 62 times. The triazole and the diketoacid moiety of S-1360 occupy a deep cavity
surrounded by I151, N155, V75, and Q62. The groups show favorable van der Waals and
electrostatic interactions with D64, I151, E152, and N155 (Figure 2). The highly favorable
binding conformations of the C active site are found 172 times. The researchers also compared
the best binding orientations of S-1360 in the active sites from the three different crystal
structures of HIV-1 integrase. Dayam and Neamati observed that S-1360 in the A active site
achieves a planar conformation and interacts with various residues throughout the active site.
In this orientation, S-1360 forms H-bonding interactions with K159 and N120. The two oxygen
Figure 2. 1BL3 active site with the residues that contribute to antiviral resistance highlighted.
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atoms from the furan ring and keto group for coordinate bonds with the Mg2+ ions. This
conformation appears to be stable because it occurs 102 out of 200 times. The binding site
conformation of S-1360 inside the C active site is also very stable because of its 172 appearances
out of 200. While these conformations of A and C are stable, this conformation is not in line
with experimentally observed results. S-1360 selectively inhibits strand transfer reactions of
HIV-1 integrase, but S-1360 in A and C did not interact with amino acids in the strand transfer
(ST) cavity. However, S-1360 did form strong interactions with various amino acids and Mg2+
ion in the cavity where 30-processing of IN is believed to be carried out.
Docking in this study was performed using version 1.2 of the Genetic Optimization for Ligand
Docking (GOLD) software. This uses a genetic algorithm to explore the ligand conformational
flexibility with partial flexibility of the active site [30]. GOLD was tested on a dataset of over
300 complexes. GOLD succeeded in more than 70% of cases in reproducing the experimental
bound conformations of the ligand [31]. GOLD requires that users define the specific binding
site. For this study, Dayam and Neamati defined a 20 Å radius active site. D64 was selected as
the center of the active site. The GOLD program then searches for a cavity within the defined
area. The program also considers all the solvent accessible atoms in the defined area as active
site atoms. “All docking runs were carried out using standard default settings with a popula-
tion size of 100, a maximum number of 100,000 operations, a mutation, and crossover rate of
95” [29]. At the end of each run, GOLD reported all the predicted bound conformations based
on their fitness score. The fitness score consists of H-bonding, complex energy, and ligand
internal energy.
2.2.3. Validating the resistance profiles of “me-too” Raltegravir analogs using docking studies
Serrao et al. sought to validate the resistance profiles of me-too Raltegravir analogs [18]. There
are minor variations in the in vitro activity of the numerous me-too integrase inhibitors. The
researchers believed that the development of me-too compounds could possibly yield a rela-
tively low amount of clinical success due to their similarities [18]. It is still possible for a
Raltegravir me-too analog to become a second-generation integrase inhibitor. To elucidate this
viewpoint, the researchers utilized the molecular docking program GOLD version 3.2 to
conduct a docking study. Serrao et al. used the structure of 1BL3 complexed with an Mg2+
ion, and various me-too compounds.
Serrao et al. proposed that residues essential to the compounds’ interaction with HIV-1
integrase would be prime candidates for resistance mutation. “Raltegravir makes direct inter-
actions with three residues encompassing the [IN] catalytic motif (D64, D116, E152)” [18]. The
researchers wanted to predict the interaction residues of Raltegravir’s analogs in a similar way.
They wanted to show that the compounds would have little success in viral eradication.
Because S-1360 was the one of the first clinical IN inhibitor candidates, the researchers thought
it would be interesting to look at the interactions between S-1360 and 1BL3 and compare with
that of Raltegravir. The researchers found that there are identical interactions between the two
drugs (D64, T66, D116, Y143, Q148, E152, and N155). Raltegravir showed an additional
interaction with E92. While this observation has been confirmed by clinical experiments, the
E92Q mutation has conferred upwards of a sevenfold viral resistance to Raltegravir [32–34].
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The researchers’ data could significantly validate the reliability of their docking technique. The
researchers then moved on to describing the interactions between HIV-1 integrase and each
most potent analog of Raltegravir. On the several compounds that were used in this follow up
study, most all of them interacted in the same binding pocket that Raltegravir is active in. If the
researchers’ predictions are correct, these candidate drugs will fail to replace Raltegravir. The
researcher’s note, while there is always the possibility for me-too drugs to evolve into block-
buster drugs, the studied HIV-1 integrase “drugs appear to have a small chance of improving
the clinical outlook of HIV patients with Raltegravir viral strains” [18].
2.3. HIV-1 protease
An essential element in the HIV life cycle is HIV-1 protease. It is a retroviral aspartyl protease.
HIV-1 protease is a homodimer, with each subunit made up of 99 amino acids [35]. Gag and
Pol polyproteins are cleaved by this protease [36]. When these are cleaved at the appropriate
places, a mature and infectious HIV virion is produced. When an effective HIV protease is
blocked, the HIV virus is not infectious [37]. HIV’s ability to replicate and infect additional
cells can be disrupted by mutation of the HIV protease active site or inhibition [38]. For this
reason, HIV protease has seen a massive amount of research money in developing HIV-1
protease inhibitors.
HIV-1 protease is a homodimeric enzyme. Two aspartic acid residues that are essential for
catalysis [39], D25 and D25, are located on each monomer. Asp-Thr-Gly sequence is present in
HIV-1 protease, but this is conserved among other mammalian aspartic protease enzymes.
There are extended beta-sheet regions on each monomer, and these are known as “the flap”.
This makes up the hydrophobic substrate binding cavity with the two aspartyl residues on the
bottom. HIV-1 proteases are highly selective, and very catalytically active in hydrolyzing
peptide bonds. While the mechanism is similar to many known features of aspartic proteases,
the full detailed mechanism of this enzyme has not been fully understood [40].
2.3.1. Saquinavir and Nelfinavir—HIV-1 protease inhibitors and their ensuing resistance
The ideal HIV-1 protease inhibitor should be potent and specific for HIV-1 protease compared
to other mammalian aspartic acid proteases [41]. The drugs should also have good bioavail-
ability and duration in human bodies. There were no known inhibitors of HIV-1 protease when
it was first determined to be a good target for antiviral therapy. A good starting place to look
was the type of enzyme that HIV-1 protease was, an aspartic acid protease.
When researchers were designing HIV-1 protease inhibitors, it was noted that there was a
stereocenter in the drug that correlated with the drug’s activity. The transition state hydroxyl
group needed to be in the R-stereochemistry or else the drug completely lost its activity. This
discovery led researchers to identify Ro-31-8959, or Saquinavir, as a prime candidate for
further studies because of this characteristic. Saquinavir has an IC50 < 0.37 nM for HIV-1
protease and does not inhibit other aspartic acid proteases, making it highly potent. While the
drug is potent, it shows poor oral bioavailability—only 4% [41]. Researchers attribute this to
the high molecular weight of the drug and the large number of amide bonds. Agouron
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Pharmaceuticals and Lilly Research Laboratories collaborated to produce Nelfinavir [42]. The
structure of Nelfinavir is very similar to the structure of Saquinavir, but Nelfinavir contains a
couple of changes. Labile components in Saquinavir were replaced with a hydroxytoluene
amide group, however, this modification resulted in reduced potency. Drug developers
replaced the phenyl group with a phenylthio group. This phenylthio group was better able to
fill the hydrophobic pocket of the HIV-1 protease active site [43]. With an IC50 = 2 nM,
Nelfinavir is also a very potent HIV-1 protease inhibitor.
As shown with HIV-1 integrase inhibitors, resistance persists to be a pressing problem in the
treatment plans for HIV-1. Because Saquinavir and Nelfinavir have similar structures, there are
different, yet highly overlapping sets of amino acids substitution mutations that confer to drug
resistance. The mutations that affect the binding site for Saquinavir are G84, I84, or L90. For
Nelfinavir, the only difference from the Saquinavir mutation is D30 instead of G48 [41]. While
these amino acids affect the binding pocket, there are other overlapping sets of amino acids
that when mutated elsewhere in the HIV-1 protease enzyme confers antiviral resistance. These
sites include L10, M46, L63, A71, and N88. Because many of the HIV-1 protease inhibitors on
the market right now are very similar in structure, it is not surprising that there is a high
degree of cross-resistance between the drugs.
2.3.2. Predicting HIV-1 protease resistance with docking studies
There are several different methods to interpret the resistant behavior of HIV-1 from genotypic
data. A physics-based approach of docking has seen an influx of use by researchers in evalu-
ating the energy interactions of the protein-inhibitor complexes. This technique has been
widely used to look at the interactions between HIV-1 protease and its inhibitors. In 2005,
Jenwitheesuk and Samudrala completed a study that used a protein-inhibitor docking
approach to determine the correlation between experimentally and computer calculated pro-
tease inhibitor binding affinities [44]. The researchers also supplemented their findings with a
molecular dynamics protocol [45]. This was used in part because most docking programs
utilize a rigid protein protocol. HIV-1 protease has special flaps that are in motion upon
binding. Since the structure of target protein is rigid, the opening and closing of the flaps is
not performed [46]. This protocol was used to simulate the flexible nature between the ligand
and the enzyme. The researchers used the X-ray crystal structures of various wild-type HIV-1
protease-inhibitor complexes. For Saquinavir and Nelfinavir, the researchers selected 1HXB
and 1OHR, respectively (Figures 3 and 4). The researchers then substituted the wild-type side
chains with a mutant side chain.
When preparing the inhibitor structure, the researchers treated them as an all atom entry. By
doing so this filled the empty valences with hydrogen. All the rotatable bonds in the inhibitors
were also allowed to rotate freely. The researchers used AutoDock version 3.0.5 with a
Lamarckian genetic algorithm to carry out docking calculations. Genetic algorithms use the
idea of natural genetics and biological evolution. There are specific values describing the
ligand with respect to the protein (translation, orientation, and conformation). These are
described at state variables and in the genetic algorithm (GA), each state variable corresponds
to a gene. In genetic algorithms, the genotype is from the ligand’s state, and the phenotype
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comes from the atomic coordinates [46]. When molecular docking is performed, the fitness of
the gene is referred to as the total interaction energy between the ligand and the protein. The
GA comes into play by mating random pairs of individuals to induce crossover. In this
scenario, some offspring undergo random mutation. The genes are selected from the current
generation based off their fitness scores. This process is repeated for multiple generations to
produce a ligand and protein interaction that has the most fitness. In the research conducted
by Jenwitheesuk and Samudrala [45], there were a total of 27,000 generations. AutoDock
generates the energy terms for inter-molecular energy, internal energy of the ligand, and
torsional free energy. When the researchers determined the final docked energy of the protein
ligand complex, the inter-molecular energy, and the internal energy of the ligand was added.
In the results of this study [45], Jenwitheesuk and Samudrala saw a significant improvement in
the correlation coefficient when supplementing their docking procedure with MD simulation
to provide a flexible nature of the protein (correlation coefficient changed from 0.38 to 0.87).
The researchers were also able to see that their docking with dynamic protocol was 64%
accurate for phenotypically resistant profiles and 83% accurate for phenotypically susceptible
groups. There was a previous study done by Shenderovich et al. [47]. While this study
followed a similar protocol to the one followed by Jenwitheesuk and Samudrala, Shenderovich
et al. only used 50 HIV-1 protease sequences. Jenwitheesuk and Samudrala used 1792 HIV-1
Figure 3. 1HXR mutated with interactions between the binding pocket and Saquinavir.
Figure 4. 1OHR mutated with amino acid interactions and Nelfinavir in the binding pocket.
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protease sequences. This larger sample size could include all of the reported resistant muta-
tions. Jenwitheesuk and Samudrala also added a protein-inhibitor relaxation feature to their
protocol. Their protocol was also able to consider the rearrangement of the side chain on the
active site surface. The relatively short MD simulation of 0.1 ps had a significant effect on the
flap region (which moved away from the binding pocket—RMSD = 0.54 Å), yet was not long
enough to affect the main chain of the protein. Using this protocol, the resistance and suscep-
tibility predictions from Nelfinavir and Saquinavir were 86 and 94%, respectively [45].
This study looked at the two key mutations discussed earlier—Asp30Asn and Gly48Val. In this
study, docking with the molecular dynamics implementations always failed to identify as a
cause of drug resistance. This suggests that researchers should not rely solely on one method
or system in making decisions about therapeutic regimens without consulting other methods,
resources, and techniques. This study was still able to determine other mutations around the
binding pocket. The docking with MD simulation implementation could identify mutations
that correspond with high levels of resistance of Amprenavir (another kind of HIV-1 protease
inhibitor)—I50V and a combination of I84V + L90 M and I54V + V82A + I84V + L90 M. These
mutations are cross resistant with Nelfinavir and Saquinavir.
2.4. Repurposing HIV-1 protease inhibitors
American trypanosomiasis, or Chagas disease, is caused by the protist Trypanosoma cruzi.
Many times there are no early signs of infection but over the course of the infection symptoms
can range from a mild fever, swollen lymph nodes, or headaches. If the infection progresses
further, the symptoms can include enlarged ventricles of the heart, which will ultimately lead
to heart failure. This infection is most common in Mexico, Central America, and South Amer-
ica, and an estimated 6.6 million people are living with this parasite [48] The most common
ways that the disease is spread are eating contaminated food, from mother to her fetus, and
blood or organ transfusions [49]. While the knowledge of this parasite has grown remarkably,
there have been no medications to treat Chagas disease in the last 40 years [50].
Over the years, there has been a recent interest in drug repurposing (also known as drug
repositioning). The process involves using known and approved medications—and sometimes
discontinued drugs from other drug trials—and using them for a new clinical applications
other than their intended treatment. Drug repurposing is gaining popularity due to the fact
that within the past few decades there has been a significant decline in the number of safe and
effective drugs being developed for the pharmaceutical market. Pharmaceutical companies are
not inclined to fund research or product design because development of a new drug is a long
and costly process [51]. One of the major benefits of trying to repurpose drugs is the reduced
cost of researching and developing a novel drug from scratch.
Bellera et al. present computer-aided identification of approved drugs Clofazimine, Benidipine,
and Saquinavir as potential trypanocidal compounds [50]. The major drug target is cruzipain
(Cz). Cz is the major cysteine protease of the parasite. This protease is essential for replication of
the intracellular form of the parasite. Bellera et al. compiled a 147 compound dataset. This data
set was balanced with 77 Cz inhibitors and 70 non-inhibitors. The researchers then used docking
studies on Saquinavir, Benidipine, Clofazimine, and the inactive verapamil. The protein to be
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used in the docking studies was 1ME4. This protein was a crystal structure of one reversible
inhibitor that was complexed with Cz. The compounds were docked according to the Lamarck-
ian genetic algorithm. The active site was defined as a 19  15  15 Å3 grid. The researchers
performed 100 docking runs for each compound. The docking active site was treated as a rigid
molecule and the ligands were treated as flexible. The researchers used Autodock 4.2 to analyze
the results of their docking study. The binding results from the docking studies correlated with
experimental evidence. The scores for Saquinavir, Benidipine, and Coldazimine were 12.76,
8.42, and 7.36 kcal/mol, respectively. However, the inactive verapamil compound was only
6.37 kcal/mol [50].
3. Identification of medicine for cancer
Cancer is one of the most devastating and destructive diseases that is known to be a persistent
public health threat. As of the year 2016, cancer is the second leading cause of death in the
United States. There were an estimated 1,685,210 new cases and 595,690 deaths resulting from
cancer [52]. Along with the high rate of incidence exacerbating the pressure already felt by
researchers to discover a cure, the mechanisms of the disease add another level of complexity
that must be outmaneuvered. Many cancer cells lack molecular targets making it extremely
difficult for anticancer chemotherapeutics to be fully effective. Toxicity against normal tissues
can develop from anticancer therapy, which leads to unwanted side effects. Due to the adverse
effects, many anticancer chemotherapeutics are given at suboptimal doses which typically
results in failure of therapy, drug resistance, and metastatic disease [53]. The complications
associated with cancer demonstrate the critical need for the development of new anticancer
therapies that are successful with minimal undesired reactions. In order to aid in the task,
many researchers are turning to in silico methods to expedite the process. Molecular docking is
one of the most popular and reliable softwares available for drug discovery, design, and
repurposing. Many researchers utilize molecular docking in cancer research because it pro-
vides great insight into protein-ligand interactions, ligand binding mechanisms, and knowl-
edge of the optimal orientation of the ligand bound to its target to form the most stable
complex. Molecular docking is an essential computational method that has demonstrated a
promising future for the evolution of more effective and potent anticancer therapies.
3.1. Docking for identifying novel proteasome inhibitors and understanding the
binding mechanisms
A variety of cancer therapeutics already exists and is available to patients; many of these
therapies attempt to have a specific molecular target in order to eradicate the cancerous cells.
One protein that receives extensive attention due to its pivotal biological role in eukaryotic
cells is the proteasome. There are two major types of proteasomes such as the 20S proteasome,
which is responsible for intracellular protein degradation and the 26S proteasome complex,
which functions in the ubiquitin pathway as an ATP-dependent proteasome [54]. The 26S
proteasome has three proteolytic activities including peptidyl glutamyl peptide hydrolase
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(PGPH) in the β1subunit, trypsin-like (T-L) in the β2 subunit and CT-L activities in the β5
subunit [55].
Degradation of proteins in the cytoplasm and nucleus of eukaryotic cells can affect: regulation
of cellular pathways particularly cell growth and proliferation, apoptosis, DNA repair, tran-
scription, immune responses, and signaling processes [56]. Inhibition of proteasomes has
therefore become an attractive target for anticancer therapies. The drug Bortezomib was
developed by Millennium Pharmaceuticals Inc. and received regular approval by the Food
and Drug Administration in 2005 as the first proteasome inhibitor to be used for the treatment
of multiple myeloma [57]. Bortezomib is a peptide boronate inhibitor of the proteasome and it
selectively binds to the protein to inhibit its chymotryptic-like activity [58]. The anticancer
effects demonstrated by Bortezomib are mainly observed by the inhibition of the transcription
factor NFkB and the promotion of apoptosis in rapidly dividing cells. While Bortezomib is
considered a successful cancer treatment, many reports of adverse side effects have driven
researchers to develop a more potent and selective proteasome inhibitor [59].
In the race to discover a more efficacious proteasome inhibitor, molecular docking has been an
extremely beneficial tool utilized by researchers to expedite the exacting process. In silico high
throughput screening of multiple chemical libraries identified the compound PI-083 as a
potential inhibitor due to its potency (IC50 = 1 μM). Molecular docking of PI-083 to the 20S
proteasome was performed by the GLIDE computer program, version 3.0 (Schrödinger, LLC,
New York, NY). The GLIDE program used for the docking and grid generation was set using
default options and parameters. The X-ray structure of yeast 20S proteasome complexed with
Bortezomib revealed that the pyrazine ring in the Bortezomib forms a hydrogen bond with
Asp114 from the β6 subunit of the proteasome. As visualized in Figure 5, Bortezomib also
forms hydrogen bonds with T21, T1, G47, and A49 residues located in the active site. PI-083
possesses a pyridine ring and it was docked to a model derived from the Bortezomib-
proteasome complex (PBD ID: 2F16). The docking studies revealed that PI-083 and Bortezomib
have similar binding mechanisms to the active site of the CT-L enzyme within the proteasome
[55]. The molecular docking combined with in vivo studies of PI-083 are indicative that the
compound is successful in tumor suppression which insinuates a need for further clinical
research in regards to PI-083 as an anticancer therapy.
Figure 5. The Bortezomib ligand positioned in the active site of the yeast 20S proteasome crystal structure. The key
residues T1, T21, G47, A49, and D114 in the active site are shown.
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Molecular docking has not only been successful in identifying potential proteasome inhibitors
but it has also been beneficial in understanding the binding mechanism of proteasome inhib-
itors to the proteasome. One study conducted by Zhang et al. was focused on MG132 (Z-
Leu-Leu-Leu-al), which is a structural component of peptide aldehydes selective and potent
against the proteasome. Using the Insight II software, the proteins and ligands were prepared
for docking. MG132 was then covalently docked to the β5 subunit of the 20S proteasome using
GOLD version 4.0. The results showed that the docking of MG132 proposed two binding
modes with low docking energies. More thorough analysis and the use of molecular dynamics
simulations revealed that binding mode I was more stable than mode II. The computational
methods utilized in this study resulted in the generation of a model that was able to re-
examine the correlation of the structure and activity of proteasome inhibitors, specifically the
interactions that take place at the P2 and P4 sites [60]. Observing the binding mode is advan-
tageous for the improvement of existing proteasome inhibitors but also for the development of
more potent inhibitors.
Ma et al. used the binding mechanism of MG132 as a comparison for docking their own series
of peptide aldehyde derivatives in which they synthesized. A total of 17 different peptide
aldehydes were developed and are listed in Table 2. Eight of the peptides are in the Cbz
class at the R4 position and the other nine peptides are in the Boc class at the R4 position.
Compounds R4 position P3 position P2 position
1 Cbz Asp(OtBu) Phe
2 Cbz Asp(OtBu) Leu
3 Cbz Glu(OtBu) Phe
4 Cbz Glu(OtBu) Leu
5 Cbz Phe Leu
6 Cbz Arg(NO2) Leu
7 Cbz Arg(Tos) Leu
8 Cbz Napa Leu
9 Boc Asp(OBzl) Phe
10 Boc Asp(OBzl) Leu
11 Boc Glu(OBzl) Phe
12 Boc Glu(OBzl) Leu
13 Boc Pro Phe
14 Boc Pro Leu
15 Boc Ser(OBzl) Leu
16 Boc Thr(OBzl) Leu
17 Boc Tyr(OBzl) Leu
Table 2. Peptide aldehyde derivatives for the inhibition of 20S proteasome activity.
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The 17 peptide aldehydes were then docked using GOLD software 4.0 with the β5 of the 20S
proteasome based on the crystal structure of the first known inhibitor MG101 complexed with
the 20S proteasome. The results of the docking experiment indicated that the size and length of
the P3 side chain is critical to the activity of the peptide aldehyde. Compounds 3 and 4 which
are part of the Cbz series synthesized by Ma et al. possess Glu(OtBu) residues at the P3 site
providing the most active inhibition. The results from docking indicated that when a phenyl
ester was used to replace a tert-butyl ester at P3 in the Boc-series, the Asp(OBzl) residue in
compound 10 exhibited more active inhibition than Glu(OBzl) residue in compound 12. Also
in the Boc-series, Ser(OBzl) in compound 15 has the most suitable length side chain because it
demonstrated the most active inhibition to CT-L active site [61]. The docking results generated
from this study highlighted the importance of the P3-position substitutes are vital for inhibitor
potency, which is essential for designing more effective proteasome inhibitors.
Peptide aldehydes are not the only compounds being considered as proteasome inhibitors for
cancer therapeutics. Santoro et al. investigated whether or not cationic and anionic porphyrins
can be used as inhibitors of the proteasome. Porphyrins are hydrophilic compounds that
possess tumor localizing properties and are used in conjunction with red light for photody-
namic therapy for the treatment of tumorous cells [62]. Cationic and anionic porphyrins were
docked using AutoDock Vina to the 20S proteasome complexed with Bortezomib (PDB: 2F16).
The cationic porphyrin H2T4 demonstrated similar inhibitory activity in all three catalytic sites
of the proteasome when observed during in vivo studies. Docking of planar H2T4 with the 20S
proteasome revealed the binding mechanism of the porphyrin to the proteasome. The results
from the docking studies reconcile with the results of the inhibition studies, indicative that
H2T4 has the potential to be a proteasome inhibitor. Along with the active ability of the
porphyrin to inhibit the proteasome, the molecules also possess low toxicity, making them an
attractive class of compounds to continue to evaluate as a form of anticancer therapy [63].
3.2. Docking for identifying inhibitors of CAs
Besides proteasomes, several isoforms of carbonic anhydrases (CAs) have become an attractive
anticancer drug target. Carbonic anhydrases are ubiquitous metalloenzymes broken up into
four unrelated gene families; the α-CAs, β-CAs, γ-CAs, and δ-CAs. Mammals have 16 α-CAs
isozymes that are different in their tissue distribution, catalytic activity, and subcellular local-
ization [64]. The α-CAs are of particular interest because they have well established catalytic
and inhibition mechanisms [65]. One α-CA in particular, CA IX, has potential to act as an
anticancer drug target as it has the ability to act as a biological marker for certain tumors [66].
CA IX is an extracellular transmembrane-bound protein located in the gastrointestinal tract.
When the enzyme is present in hypoxic conditions, CA IX is overexpressed and is observed to
be associated with different types of cancer cells via the hypoxia inducible factor-1 (HIF-1).
Overexpression also causes the environmental pH of a tumor to be lowered to acidic condi-
tions [66]. The appeal of the CA IX as a potential anticancer drug is demonstrated by the fact
that the enzyme has restricted expression in normal tissues (Table 2).
Amresh et al. used molecular docking and several others in silico methods to discover five
potential CA IX inhibitors. AutoDock 4.2 was used to dock all the inhibitors to the crystal
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structure of CA IX (PDB: 3IAI) visualized in Figure 6. Coulombic electrostatic potential, van
der Waals interaction represented as a Lennard-Jones12-6 dispersion/repulsion term and
hydrogen bonding were addressed when evaluating the binding energy during docking.
Docking orientations within 2.0 Å in root-mean square deviation tolerance were the parame-
ters set in order to obtain the most favorable free energy of binding. The inhibitors with the
best docking poses and scores were then subjected to post-docking energy minimization on
Discovery Studio 3.5. The final structures were analyzed using PyMOL visualization programs
and the receptor-inhibitor complexes were used to develop the pharmacophore model for
further evaluation [67]. Docking simulations were also performed in order to identify the
residues present in the active site of CA IX that interact with the inhibitors. The docking study
revealed that residues: L91, L93, L198, V121, L135, L141, V143, P201, P202, W5, W209, F245,
H96, H119, E106, T199, T200, H94, D132, Q92, and V131 formed either hydrophobic or aro-
matic interactions with the inhibitor. N62, H64, S65, Q67, T69, and Q92 were identified as the
hydrophilic residues in the active site as well [67]. The results of the docking studies
established 10 novel compounds as CA IX inhibitors. Further analysis of the docking scores
narrowed the list even further to the top five scoring compounds which were: ZINC03363328,
ZINC08828920, ZINC12941947, ZINC03622539, and ZINC16650541 [67]. The information
obtained from this study has demonstrated the value of molecular docking in identifying new
CA IX inhibitors that provide a promising future as an anticancer therapy.
3.3. Docking for identifying inhibitors of EGFR
The epidermal growth factor receptor (EGFR) is another enticing biological target in the
development of anticancer therapeutics. The EGFR is a family of tyrosine kinases that regulate
many developmental, metabolic, and physiological processes. Binding of the epidermal
growth factor to the family of kinases leads to homodimerization or heterodimerization of the
EGFR. Mutations of EGFR gene, over expressed copies of the gene and EGFR protein
overexpression lead to dysregulated TK activity which is observed in many tumors [68].
Overexpression of EGFR is frequently observed in breast, lung, ovarian, and prostate cancer
Figure 6. The critical residues in the active site located on the CA IX (PDB: 3IAI): L91, L93, L198, V121, L135, L141, V143,
P201, P202, W5, W209, F245, H96, H119, E106, T199, T200, H94, D132, Q92, N62, H64, S65, Q67, T69, and Q92 are
displayed.
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and is associated with aggressive tumor behavior [69]. The EGFR is the main activator in the
downstream pathways for survival and growth signals such as p42/44 MAPK and PI3K/AKT
pathways [70]. Inhibition of these pathways leads to apoptosis of cancer cells, making the
EGFR a particularly promising area of cancer research.
The mutations G719S, L858R, T790M, G719S/T790M, and T790M/L858R are commonly seen in
patients with cancer because they modify the EGFR kinase activity [71]. García-Godoy et al.
used molecular docking in order to study the interactions of EGFR inhibitors on the wild-type
EGFR and mutant EGFR. For the wild-type human EGFR, the EGFR (PDB: 4ZAU) was
complexed with the ligand AZD9291. Docking was also conducted on the EGFR containing
the G719S mutation and the L858R mutation. The EGFR (PBD ID: 2ITN) was used with the
G719S mutation and the EGFR (PDB: 2 EB3) was used with the L858R mutation. Both EGFRs
were in complex with AMP-PNP. Results of this docking study indicated that in both com-
plexes, M793 was an important residue in facilitating interactions between the ligand and the
active site [71]. In the final docking study, docking was performed on the EGFR double
mutants T790M/L858R and T790M/G719S. In the instance where the EGFR mutant T790M/
L858R was docked, the EGFR (PDB: 4JR5) was used and it was complexed with the ligand
3QY. The double mutant EGFR T790M/G719S (PDB: 3UG2) was also used and it was
complexed with getfitinib (PDB: IRE). In both of the docking studies, the results revealed that
there is a critical interaction between the ligand and the Met793 residue in the active site of the
mutant EGFR [71]. Analysis of the results concluded that the interactions displayed in each
case can be crucial evidence to why different cancer patients are more or less sensitive to
certain treatments. This provides insight into how certain therapies should be considered
circumstantial based on the mutation a patient may possess. The in silico methodology utilized
in this study set a precedent for other researchers to use molecular docking to discover more
drugs for EGFR inhibition.
Mahajan et al. discerned the value of the EGFR as a target for anticancer therapy; using
molecular docking they were able to discover potential EGFR inhibitors. Screening of 50,000
compounds was performed by LigPrep (version3.3; Schrodinger, LLC, 2015) in order to prepare
a library of drugs to be tested by several in silico methods. After the library was prepared with
LigPrep, the compounds were then screened against EGFR drug target using e-Pharmacophore,
docking, pharmacophore, substructure, and similarity search [72]. The protein used in the
docking studies is complexed with the inhibitor tak-285 and it was chosen for the study because
it has the best X-ray resolution (1.50 Å) of the EGFR structure (PDB: 3POZ). The downloaded
protein was prepared for docking using the Protein Preparation Wizard. Docking the com-
pounds was performed by the Glide module (version3.6; Schrodinger, LLC, 2015) software
and the first round of docking studies used the high throughput virtual screening setting. After
all compounds had been screened, the top 30% of the best scoring compounds were then re-
docked using standard precision (SP) docking. Once those compounds had been docked, the
top 30% of the best scoring compounds in SP docking were then re-docked using extra precision
(XP) docking. A total of 1534 had been selected as compounds that bound to the EGFR with a
respectable docking score [72]. Docking, along with e-Pharmacophore and pharmacophore in
silico methods were able to narrow 50,000 compounds down to 200 compounds that showed
potential for EGFR inhibition. Further computational methodology of the compounds revealed
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that 87 out of the 200 compounds form an H-bond with M793, a critical residue in the inhibition
of EGFR which can be visualized in Figure 7. Docking also revealed the structural similarity
between the compounds and how the compounds orient themselves in the active site [72]. The
87 compounds were then categorized into 12 structural moieties which provided critical struc-
tural modification suggestions that would be beneficial in the development of more potent
EGFR inhibitors [72].
3.4. Repurposing approved drugs to anticancer applications
Molecular docking for drug repurposing is another effective and beneficial method that
many researchers utilize in order to discover new indications for already existing drugs.
The technique is especially favorable when assessing different pharmaceuticals as potential
anticancer therapies. Avastin, which was originally developed for metastatic colon cancer
and non-small cell lung cancer, has now been approved for metastatic breast cancer. Rituxan,
which was intended for non-Hodgkin’s Lymphoma has been repurposed for chronic lym-
phocytic leukemia and rheumatoid arthritis [51]. Molecular docking to make predictions of
the physical interactions between the ligand and the target has been a successful practice in
drug repurposing.
Avastin and Rituxan are not the only two drugs that have been repurposed for anticancer
therapeutics. Oliva et al. used molecular docking to aid in the study of repurposing the FDA
approved psychotropic drug Chlorpromazine. Evidence had shown that Chlorpromazine had
antiproliferative activity against colon and brain tumors [73]. The drug accomplished this by
inhibiting cytochrome c oxidase (CcO), which is the terminal electron acceptor enzyme of the
mitochondrial respiratory chain and is composed of 13 subunits [74, 75] . Cytochrome c oxidase
subunit 4 isoform 1 (COX4-1) was the focus of the study because in patients with glioblastoma,
increased expression of COX4-1 has been associated with Temozolomide chemoresistance [73].
In vitro studies indicated that Chlorpromazine inhibited CcO when COX4-1 is expressed,
however the binding mechanism was not well understood. Using Schrödinger Suite 2015
(Schrödinger, LLC, New York, NY, 2015), two human CcO homology models were constructed
based on the mouse CcO crystal structure (PDB: 2Y69) using the Prime program. The Chlor-
promazine ligand was prepared using the LigPrep program and the docking studies were
Figure 7. The tak-285 inhibitor complexed with the EGFR tyrosine kinase domain. The critical residue Met793 is shown in
the active site of the EGFR tyrosine kinase.
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conducted using the Glide program. The docking results showed that Chlorpromazine binds to
a hydrophobic pocket formed by residues from COX4 and transmembrane helices of COX1.
L129, K122, M119, and Y126 were identified as being important residues that displayed inter-
actions with the Chlorpromazine [73]. The results also indicated that the Chlorpromazine
overlaps with residues of COX11, preventing the subunit from interacting with the rest of the
CcO complex [73]. The study provides critical evidence on the repurposing for Chlorpromazine
as a treatment for chemoresistant gliomas and persuades future research on Chlorpromazine as
an anticancer therapy.
In silico methods have been played an essential role in the battle against many of world’s most
devastating diseases. Cancer is debilitating, painful, and in some cases lethal; there is a mas-
sive urgency for researchers to find a cure so patients no longer have to suffer. Molecular
docking has been on the forefront for the development, design, and discovery for new antican-
cer therapeutics. Among other things, one of the most important features of molecular docking
is that it provides researchers with the opportunity to examine specific interactions between
the ligand and the molecular target that are not well understood by in vivo and in vitro
methods. Detailed knowledge of the binding interactions and mechanisms of the ligand to the
target is critical for the production of new drugs or the improvement of the already existing
drugs. Molecular docking is a dependable, economic, and an expeditious process that is of
paramount importance in the advancement of anticancer therapeutics.
4. Identification of medicine for other prevalent diseases
4.1. Influenza
Influenza, commonly referred to as the flu, is a viral infection that can be mild or severe,
depending on the strain, and the host it infects. Due to the rapidly mutating nature of the
influenza virus, new vaccines must be made and administered annually. Each year, researchers
must determine which strains of the influenza virus are most likely to become prevalent in the
coming flu season; annual flu vaccines are manufactured based on those recommendations
[76]. Unfortunately, there is always the threat that the virus may mutate after that decision has
been made, rendering vaccines ineffective. In that case, flu outbreaks and even pandemics may
occur. In a pandemic, vaccination will no longer be a feasible option, and antiviral agents will
become a critical resource [77].
There are two types of antiviral drugs that have been used to treat influenza. The first
marketed influenza antivirals were Adamantanes, specifically Amantadine and Rimantadine
(Figure 8A, B). Adamantanes function by blocking the M2 proton channel [78]. This class of
drugs was effective against influenza type A, but drug resistance developed rapidly [79, 80].
Hayden et al. conducted a study in which 17 Rimantadine-resistant influenza strains were
recovered from 13 patients [81]. The M2 coding sequences of 17 resistant strains were then
compared to 8 drug sensitive strains, and it was determined that all resistant strains had a
nonsynonymous substitution in RNA segment 7. The most common mutation was S31N,
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which was found in 14 separate isolates. The other mutations found were A30V, A30T, and
V27A. By 2009, all strains of influenza A had become resistant to Adamantanes [82].
The second class of influenza drugs is neuraminidase inhibitors. Neuraminidase, also referred
to as sialidase, is an enzyme involved in the release of viral progeny. At the end of the viral
replication cycle, neuraminidase cleaves O-sialic acid, also called NeuAc5 (N-acetyl-alpha-
neuraminate), during the budding process that releases viral progeny that then infect other
cells. Because inhibition of this enzyme greatly reduces the spread of the virus throughout the
body, it is an attractive drug target [83]. There are currently two neuraminidase inhibitors on
the market: Zanamivir (Relenza) and Oseltamivir (Tamiflu). Zanamivir (4-guanidino-Neu5-
Ac2en) was created using computer-assisted rational design based on the X-ray diffraction
structure of influenza neuraminidase, which was first solved by Varghese et al. (now PDB:
7NN9) [84]. In further studies, Colman et al. characterized the active site of this protein,
identifying a large pocket containing “an unusually large number of charged residues,”
including R119 and E1201 [86]. Von Itzstein et al. used GRID software to analyze the active site
of influenza neuraminidase and its interactions with various novel inhibitors [87]. The inhibi-
tor with the most energetically favorable interactions was 4-guanidino-Neu5Ac2en, now
known as Zanamivir. It was noted that one of the terminal amino groups of Zanamivir’s
guanidyl group interacted with the glutamic acid 119 carboxyl group (Figure 9A, B). Von
Itzstein et al. went on to conduct Zanamivir trials on influenza infected ferrets and mice, which
validated the results of their computational studies [87]. Hayden et al. conducted randomized
double blind trials that concluded Zanamivir was both effective and safe for use to treat
influenza A and B [88]. The drug became FDA approved in 1999 and has since been used in
conjunction with annual vaccines to prevent and minimize influenza outbreaks [89].
4.2. Malaria
Malaria is an infectious disease caused by a parasitic protist and spread by mosquitoes. There
are several different species of this parasite; the most deadly, and most prevalent is Plasmodium
1
Colman et al. (1983) refers to Arg 119 and Glu 120 as Arg 118 and Glu 119. This text uses the more up to date numbering
used in [85].
Figure 8. Two dimensional structures of the Adamantanes, (A) amantadine [SMILES: NC13CC2CC(CC(C1)C2)C3] and
(B) Rimantadine [SMILES: NC(C)C13CC2CC(CC(C1)C2)C3].
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falciparum. This disease can cause flu-like symptoms, and can be fatal if left untreated [90].
Malaria is typically treated with quinine drugs such as Chloroquine, Hydroxychloroquine, or
Amodiaquine (Figure 10A, B), which function by interfering with heme polymerization [91].
Interference with this function leads to increased levels of hemoglobin and ferriproto-
porphyrin IX (FPIX), which can be toxic to the parasite. P. falciparum has developed resistance
to chloroquine (and similar drugs); in resistant cells, quinine drugs are actively transported out
of the parasitic vacuole [92]. This form of resistance has become widespread, resulting in a
need for new antimalarial drugs.
In P. falciparum, M18 aspartyl aminopeptidase (PfM18AAP) and its interactions with mem-
brane proteins are essential for parasite survival, making it an attractive antimalarial drug
target. Using molecular docking and other computational methods, Kumari et al. determined
structural requirements for PfM18AAP inhibitors using GOLD v5.2 and the Schrödinger Mae-
stro 9.1 GLIDE program [12]. This study selected and screened just under 30,000 compounds
Figure 10. Two-dimensional structures of the common quinine drugs, (A) Amodiaquine [SMILES: Clc1cc2nccc(c2cc1)
Nc3cc(c(O)cc3)CN(CC)CC] and (B) Chloroquine [SMILES: Clc1cc2nccc(c2cc1)NC(C)CCCN(CC)CC].
Figure 9. (A) (PDB ID: 5 L17) this structure shows Zanamivir bound to influenza a neuraminidase. Zanamivir, shown
with green carbons, interacts with R119, E120, L135, D152, R153, W180, I224, R226, E229, E278, E279, R294, R372, and
Y406 (cyan carbons). (B) Ligand interaction diagram showing a closer look at how these residues interact with the ligand.
Note the interaction between amino groups and acidic residues (primarily glutamic acid) and the interactions between
hydroxyl groups and basic residues (primarily arginine).
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for binding activity. Based on the results, it was concluded that the best inhibitors had one
hydrogen donor, one hydrophobic group, and two aromatic rings. Molecular docking and
pharmacophore modeling have been used to search for novel inhibitors using those criteria.
The lactate dehydrogenase enzyme of P. falciparum (PfLDH) is a target of quinine drugs, and is
another potential target for novel antimalarial drugs. This enzyme is important for glycolysis,
and its inhibition can potentially result in death of the parasite [93]. Compounds similar to
nicotinamide adenine dinucleotide (NADH) are believed to be excellent candidates for PfLDH
inhibition [94]. Penna-Coutinho et al. used molecular docking (with software MolDock) to select
potential drug candidates [95]. NADH and 50 potential drug candidates were docked to PfLDH
in complex with Oxamate (PDB: 1LDG), the substrate that NADH binds to (Figure 11); the
compounds that had the most similar docking score to NADH were selected for in vitro tests.
The in vitro tests confirmed the activity of the highest scoring compounds, Itraconazole, Atorva-
statin, and Posaconazole. In further tests, these same compounds inhibited parasite growth in
mice infected with Plasmodium berghei, another species of the malaria parasite. These compounds
require further testing, but could potentially progress to clinical trials and eventually be
marketed as antimalarial drugs.
4.3. Zika
The Zika virus (ZIKV), named for the Ugandan forest in which it was originally found, was
first isolated in monkeys [96]. ZIKV belongs to a genus of viruses known as flaviviruses; other
viruses belonging to this genus are dengue fever, yellow fever, hepatitis, and West Nile. ZIKV
can be transmitted by mosquitoes or sexual contact. Symptoms of the virus include fever, joint
pain, and rash for up to 7 days. ZIKV has also been associated with Guillain-Barre syndrome
[97], an autoimmune disease. The virus can also be transmitted from mother to fetus, which
can result in severe birth defects. From 2007 to 2014, several small outbreaks of the virus were
Figure 11. Structure of plasmodium falciparum lactate dehydrogenase in complex with Oxamate and NADH. NADH
[SMILES:O=C(N)c1ccc[n+](c1)[C@@H]2O[C@@H]([C@@H](O)[C@H]2O)COP([O-])(=O)OP(=O)(O)OC[C@H]5O[C@@H]
(n4cnc3c(ncnc34)N)[C@H](O)[C@@H]5O]; Oxamate [SMILES: C(=O)(C(=O)O)N].
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reported [97–99]. In 2015, the first ZIKV epidemic began in Brazil. As outbreaks become more
and more severe, it is becoming increasingly urgent to find a drug to treat ZIKV.
Non-structural protein 5 methyl transferase (NS5 MTase) is crucial for the maintained stability
of a flaviviral genome, and the ability to evade immune response [100] which makes it an
attractive target for antiviral activity. Zhang et al. used docking simulations (AutoDock 4.2) to
determine potential designs for novel NS5 MTase inhibitors and binding sites [101]; the
authors of this study found that dengue virus inhibitor compound 10 found by Lim et al.
[102] (PDB: 3P8Z) may bind to ZIKV NS5MTase. Ramharack and Soliman utilized several
different computational tools in their study. Preliminary methods included homology model-
ing, binding site prediction, and pharmacophore modeling [103]. To narrow down the results
from these studies, they used molecular docking [AutoDock Vina]. Out of 31 compounds
subjected to docking studies, 3 were chosen for the next step, molecular dynamic simulation.
It was concluded that two of their compounds showed “substantial stability in complex with
the target enzyme (ZIKV NS5),” [103].
Hepatitis C is another virus that is closely related to Zika. Hepatitis C is commonly treated
with polymerase inhibitors (Ribavirin and Sofosbuvir). Sacramento et al. used docking simu-
lations (MODELER 9.16) to model binding between Hepatitis C polymerase inhibitors and
Zika RNA polymerase (PDB: 4WTG) [104]. These simulations, as well as their in vitro trials
suggested that these drugs intended for treatment of Hepatitis C may be effective against Zika
as well. A study by Elfiky supported these results through further docking simulations
(SCIGRESS software with PDB: 2J7U) [105].
4.4. Tuberculosis
Tuberculosis (TB) and infectious disease caused by Mycobacterium tuberculosis. Human infec-
tion with TB dates back all the way to ancient Egypt, India, and China [106]. TB is spread
through the air, usually by a cough or sneeze from an infected person. TB kills nearly 2 million
people each year, mostly in Africa [107]. The most effective treatments for non-resistant TB are
Isoniazid and Rifampin. Unfortunately, TB drug resistance has become extensive [107]. There
are three categories of resistant TB strains: multidrug resistant (MDR), extensively drug-
resistant (XDR), and totally drug-resistant (TDR). In order to be classified as MDR TB, the
strain must be resistant to both Isoniazid and Rifampin [108]. A TB strain is classified as XDR if
it is resistant to Isoniazid, Rifampin, and “is also resistant to three or more of the six classes of
second line TB drugs,” [108]. TDR strains are resistant to all known TB drugs [109]. Dramatic
increases of drug resistance have prompted researchers to seek new drug targets; in order to
reduce research costs and get results as quickly as possible, many are turning to docking
simulations for preliminary trials.
Shikimate kinase is a protein involved in an amino acid biosynthesis pathway inM. tuberculosis
[110]. Interruption of this pathway prevents synthesis of essential amino acids, leading to
incomplete proteins, which leads to cell death. Vianna and de Azevedo used docking simula-
tions (MOLDOCK) to identify novel SK inhibitors; these compounds were compared to
staurosporine, which has demonstrated SK inhibition in vitro [111]. The novel inhibitors were
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docked to a number of structures for MtSK (PDB: 2DFN, 1U8A, 1WE2, 1ZYU, 2G1K, 2IYQ,
2IYR, 2IYS, 2IYX, 2IYY, 2IYZ, and 3BAF).
Another response to drug resistance is drug repurposing. The advantage of drug repurposing
is that potential drugs have already been shown not to have severe side effects, which speeds
up the process and saves money. Studies of this nature often utilize molecular docking and
other computational methods to save even more time and money by screening more potential
drugs in a shorter time frame. Kahlous et al. selected 1991 FDA-approved (nonantibiotic)
drugs and tested them for antibiotic activity against Staphylococcus aureus [PDB: 2XCS and
2XCT] by docking (OpenEye HYBRID) drug structures to known antibiotic targets [112]. These
results were then compared to a variety of market antibiotics. The drug candidates were
narrowed down to 34 potential candidates for further testing. Among the top candidates were
Diclofenac (antiinflammatory), Drotaverine (antispasmodic), Flurbiprofen (antiinflammatory),
Ibuprofen (antiinflammatory), and Niacin (vitamin B3). Brindha et al. conducted a similar
study, specifically targeting tuberculosis [113]. This study screened 1554 FDA-approved drugs
(Schrödinger GLIDE) for their ability to bind to protein kinase B of M. tuberculosis (PDB:
2FUM), a known antibiotic target. Fourteen of these drugs were determined suitable for
further exploration as TB drugs. The top three candidates from this study were Flavin adenine
dinucleotide (treats vitamin B2 deficiency), Valrubicin (treats bladder cancer), and Arcarbose
(treat/manage type II diabetes).
5. Summary and discussion
While in silicomethodsmust be reaffirmed by in vitro and in vivo testing, computationalmethods
have been gaining popularity in the drug design industry by proving they are critical in the
discovery of medications. Several drugs that are currently available to the public for the treat-
ment of different diseases have been developed based on in silico approaches. For example,
Zanamivir, used to treat influenza, was developed using computer-assisted design [84].
Through these studies, Zanamivir was identified as the inhibitor having the most energetically
favorable interactions with influenza neuraminidase. The results from the docking study of
Zanamivir were convincing enough to move forward with in vivo testing; the results of in vivo
studies reaffirmed the results of the in silico tests [87]. Nelfinavir and Saquinavar are used in the
treatment of HIV and were also developed by computational methods. Docking studies also
revealed how the HIV protease developed resistance toward Nelfinavir and Saquinavar which
was beneficial in improving the potency of the drugs [45]. Based on these successful examples, it
is clear that computational methods are capable of developing new pharmaceuticals and pro-
vide evidence to other researchers that this is a reliable and effective technique in drug discovery.
The cost of bringing a drug to market and the amount of drug resistance profiles emerging are
major factors that researchers need to address when designing a drug. It may cause more than
1 billion dollars and 10 years to bring a drug to the market [114]. As we have collected millions
of pharmaceutical compounds in a database like Pubchem [115] and ChEMBL [116], we will
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need several months or even years to screen them all manually or automatically in the lab, if it
is possible we can obtain them all. More and more researchers are turning to computational
methods to design drugs in an efficient manner that has the possibility to save money for
pharmaceutical companies. While these in silico methods are not yet ready to replace in vivo
and in vitro methods and have only brought a few medications to the market, such Raltegravir
and Dorzolamide [117], they still provide a valuable insight into the molecular interactions
between the ligand and protein. As seen above, there are situations in which computational
methods are not always able to accurately determine the results. For this reason, many
researchers use in silico methods in tandem with other research methods to verify or elucidate
standing results. Each time these computational methods verify already established experi-
mental results, their validity in the drug design market has the opportunity to go up. It seems
that many researchers are starting to rely on computational results from molecular docking
and other computational methods in their research. Often these methods cannot solely gener-
ate results that will create a novel drug. However, computational methods are slowly solidify-
ing their place in the pharmaceutical industry as a necessary step toward designing new drugs.
To summarize the cases we reported above (Please see Table 3):
1. Most of these projects were designed to recognize a new inhibitor(s) to an enzyme which
plays an essential role in a key metabolic/proliferation pathway or the infectious procedure
of a pathogen.
2. One or more determined PDB structures of the target protein with good resolution were
used, and, often, the key residues of the catalytic reaction, binding/inhibition mechanisms,
and drug resistances were revealed based on the docking results.
3. Other computational methods or tools were also used in sequence or in parallel, such as
structure prediction, binding site prediction, pharmacophore model, QSAR model, and
MD simulation.
4. Drug repurposing has received more and more attention.
Enzymes and membrane proteins (receptors) are two major drug targets. According to previous
studies, there is severe bias on the number of determined structures deposit on PDB [118, 119]. A
large proportion of solved structures belong to soluble proteins, especially enzymes. It not only
made structures of enzymes easier to obtain for molecular docking, but it also made scoring
functions/force fields of molecular docking and other related computational approaches to be
more accurate for enzymes than membrane proteins. However, we have noticed the importance
of membrane receptors, glycol-proteins and non-structure proteins. How to create a reliable
strategy to determine or predict the structures of these important drug targets remains a big
challenge in molecular docking.
Drug resistance is also a major issue in the failures of treatment of both cancers and infectious
diseases. Due to the advancement of docking calculation, we will be able to predict the
possible drug resistances and side effects before the treatment or even the drug approval in
the future. Therefore, the back-up drugs should be developed and utilized even before drug
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resistance occurs. The improved reliability of molecular docking also facilitates the precision
medicine.
As we see in Figure 1, the computational approaches play key roles in different steps of the
drug discovery process: obtaining the protein structures, binding site prediction, virtual drug
screening, binding verification, binding affinity estimation, prediction of drug resistances, bind-
ing kinetic modeling, and so on. Molecular docking assists in achieving many objectives in the
steps mentioned above effectively and efficiently. Often, it is cheaper, faster than performing
Disease Target protein PDB
ID
Docking
Software
Drug(s) Purpose Other
computational
method(s) used
HIV Integrase 1QS4,
1BIS,
1BLE
GOLD S-1360 To predict the
binding mode
HIV Protease 1HXB,
1OHR
AutoDock Saquinavir, Nelfinavir To predict the drug
resistance
MD simulation
Cancer Proteasome 2F16 Glide,
GOLD
PI-083, MG132, peptide
aldehydes
To identify new
drug, to understand
the binding
mechanism
MD simulation
Cancer Carbonic
anhydrases IX
3IAI AutoDock ZINC03363328,
ZINC08828920,
ZINC12941947,
ZINC03622539,
ZINC1665054
To discover
inhibitors
Post-docking
energy
minimization
Cancer EGFR 2ITN
et al.
AutoDock,
jMetalCpp
AMPPNP, Dacomitinib,
et al.
To study the effects
of mutations
Optimization
algorithms
Cancer CcO 2Y69 Glide Chlorpromazine Drug repurposing
Influenza Neuraminidase 7NN9 GRID Zanamivir To analyze the active
site
Malaria M18 aspartyl
aminopeptidase
4EME GOLD,
Glide
CHEMBL588000 et al. To identify new
drugs
Pharmacophore
and QSAR
models
Malaria Lactate
dehydrogenase
1LDG MolDock Itraconazole, Atorvastatin,
Posaconazole
To select potential
drugs
Zika NS5MTase 3P8Z AutoDock New candidates To identify new
drugs
MD simulation
Zika RNA
Polymerase
4WTG Modeler Ribavirin, Sofosbuvir To model and
compare ligand
binding
TB Shikimate
kinase
2DFN
et al.
MOLDOCK New candidates To identify new
inhibitors
TB Shikimate
kinase
2XCS,
2XCT,
2FUM
OpenEye
HYBRID,
Glide
Diclofenac et al. Drug repurposing
Table 3. Summary of the cases presented.
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experiments in the biological labs, and we can do even more than conventional approaches. For
example, we can predict the potential side effects or drug resistances. Other computational tools
such as (3D structure or binding site) prediction models, molecular dynamic simulation, and
kinetic modeling have been also well established and applied in different steps of drug discov-
ery to provide more information of target protein or drug efficacy, narrow down the searching
spaces/reduce computational load, and/or validate the results of docking. Moreover, drug
repurposing is another important application of molecular docking that helps us to enhance
the cost- and time-effectiveness of drug development.
In the Era of “Big Data”, the accumulated number of protein structures and upgraded compu-
tation software and hardware generally improved all related computational methods, not just
molecular docking. Based on the progress of the knowledge on protein folding, structural
flexibility and molecular recognition, molecular docking has matured. As the core technology
of virtual drug discovery, molecular docking will be widely applied to many stages of the drug
discovery process.
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